Image Image Image Image Image Image Image Image Image Image
Accessibilitat
Aneu a dalt

Amunt

hemorragia subretinal

· 01/12/2012

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and high visual acuity.

multifocal ERG

· 01/07/2011

Update on Geographic Atrophy in Age-Related Macular Degeneration.

Foto51_3

· 01/04/2010

Ranibizumab in the treatment of choroidal neovascularization on the border of an inferior staphyloma associated with tilted disc syndrome.

40MPU-CR-GLY-SYN_Snapshot_01 para RESULTADOS ALFA-SYN 1

· 01/05/2011

Management of Retinal Vein Occlusion – Consensus Document.

color atrofia

· 01/02/2010

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.

_MG_7582

· 24/04/2010

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

AF EMQ

· 01/12/2011

Postsurgical cystoid macular edema

Oclusión venosa

· 10/08/2010

Retinal vein occlusions.

DMAE

· 26/03/2013

As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. (FALTA)

DMAE

· 08/10/2010

A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice.

40MPU-CR-GLY-SYN_Snapshot_01 para RESULTADOS ALFA-SYN 1 GABA Y GLY

· 03/01/2013

Optical Coherence Tomography Assessment of Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to Geographic Atrophy.

Foto51_2

· 26/03/2013

GAIN. Characterization of geographic atrophy progression in patients with age-related macular degeneration: evolution and risk factors associated with geographic atrophy progression

Foto49_3

· 26/03/2013

Oral Omega 3 Drusen: A phase II randomized, double-mask study to establish the safety and efficacy of High-Dose Oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular degeneration 

Foto46-2

· 26/03/2013

The Brighter Study: a 24-month, phase IIIB, open-label, randomized, active controlled, three-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)

Foto46_3

· 26/03/2013

The Crystal Study: a 24-month, phase IIIB, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)

Última modificació: 17 Juliol, 2019 - 14:57